Description
Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Methocarbamol Injection |
| Generic Name | Methocarbamol (3?(2?methoxyphenoxy)?1,2?propanediol 1?carbamate) |
| CAS Number | 532?03?6 nmpa.gov.cn+10drugs.com+10my.clevelandclinic.org+10ncbi.nlm.nih.gov+1medcentral.com+1my.clevelandclinic.org+7zh.wikipedia.org+7chemicalbook.com+7 |
| Molecular Formula | C??H??NO? |
| Molecular Weight | ~241.24?g/mol |
| Dosage Form | Sterile injectable solution for IV/IM use |
| Strength | 100?mg/mL; 1?g per 10?mL vial |
| Pack Size | Single vial per box |
| Approval Number | N/A (research-use product) |
| Product Code | N/A |
| Manufacturer | (Specify your company) |
| Storage | Store at room temperature; protect from moisture and heat |
| Intended Use | Laboratory research only |
Mechanism of Action
Methocarbamol acts centrally by depressing nerve impulses (CNS depressant effect), reducing muscle spasms without directly affecting skeletal muscle fibers .
Research Applications & Pharmacology
Pain/spasm models: Used in preclinical models of musculoskeletal injury, tetanus, and spasticity assays .
Pharmacokinetics:
Administered as 1?g IV or IM per dose, up to 3?g/day for 3 days maximum.
Plasma half-life ~1–2?hrs; protein binding ~46–50%; metabolized via dealkylation/hydroxylation and excreted renally.
Safety Profile & Handling
Common effects: Drowsiness, dizziness, headache, nausea; injection-site discomfort .
Precautions: May impair cognition—avoid during anesthesia or behavioral assays. Avoid use in seizure-prone or renally impaired models .
Handling: Use PPE, administer slowly IV/IM, monitor vitals post-injection, and dispose of pharmaceutical waste properly.
?? Research?Use Disclaimer
This product is intended solely for laboratory research. It is not approved for human, clinical, diagnostic, therapeutic, or veterinary applications. Misuse may lead to adverse events and invalidate research results.


Reviews
There are no reviews yet.